Premium
Fine‐needle aspiration biopsy of non‐Hodgkin lymphoma for use in expression microarray analysis
Author(s) -
Morrison Carl,
Palatini Jeff,
Riggenbach Judy,
Radmacher Michael,
Porcu Pierluigi
Publication year - 2006
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.22174
Subject(s) - medicine , trizol , biopsy , lymphoma , fine needle aspiration , ex vivo , in vivo , lymph node , pathology , lymph node biopsy , lymph , gene expression , radiology , rna extraction , gene , biology , biochemistry , microbiology and biotechnology
BACKGROUND The majority of patients with lymphoma undergo a single biopsy for diagnosis, and there are few opportunities to acquire posttreatment material. Fine‐needle aspiration (FNA) biopsy is a minimally invasive procedure, and acquiring routine posttreatment material would require minimal effort and provide needed material for gene expression profiling. METHODS Ex vivo FNA biopsies were performed using a standard clinical technique with 21‐gauge, 22‐gauge, 23‐gauge, and 25‐gauge needles for 8 lymph node specimens and were collected in either RNA stabilization reagent (RNA later ) or Trizol. Eight patients with known or suspected Non‐Hodgkin lymphoma (NHL) underwent interoperative (in vivo) FNA biopsies based on the best technique derived from the ex vivo aspirates. RNA derived from the in vivo FNA biopsies and the matched, snap‐frozen surgical lymph node biopsy remnant was used for gene expression analysis with proprietary U133A chips. RESULTS The results confirmed the authors' experience, that RNA isolated from FNA biopsies of lymph nodes collected in Trizol is superior both quantitatively and qualitatively to RNA collected in RNA later . Gene expression profiles of NHL derived from in vivo FNA biopsies and matched, frozen surgical specimens showed good overall correlation. CONCLUSIONS High‐throughput gene expression analysis in patients with NHL derived from material acquired by FNA biopsy is a feasible approach to developing a platform for real‐time analysis of treatment responses in this group of patients. Cancer (Cancer Cytopathol) 2006; © 2006 American Cancer Society.